Published in Antivir Ther on January 01, 2007
Effects of mutagenic and chain-terminating nucleotide analogs on enzymes isolated from hepatitis C virus strains of various genotypes. Antimicrob Agents Chemother (2008) 1.00
Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. J Virol (2013) 1.00
Favipiravir elicits antiviral mutagenesis during virus replication in vivo. Elife (2014) 0.93
Selection of hepatitis C virus resistant to ribavirin. Virol J (2011) 0.86
Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis. PLoS One (2013) 0.81
Viral Load Analysis of Hepatitis C Virus in Huh7.5 Cell Culture System. Jundishapur J Microbiol (2015) 0.80
Enhanced anti-HCV activity of interferon alpha 17 subtype. Virol J (2009) 0.78
Sensitivity of a ribavirin resistant mutant of hepatitis C virus to other antiviral drugs. PLoS One (2013) 0.75
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 10.20
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem (2003) 4.58
Structural biology of hepatitis C virus. Hepatology (2004) 3.40
Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol (2006) 3.33
Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology (2005) 2.93
Characterization of functional hepatitis C virus envelope glycoproteins. J Virol (2004) 2.40
High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem (2005) 2.31
Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol (2005) 2.19
High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem (2006) 2.02
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol (2006) 1.99
Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol (2004) 1.98
Hepatitis C virus entry: potential receptors and their biological functions. J Gen Virol (2006) 1.96
Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl Acad Sci U S A (2007) 1.89
Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J Virol (2002) 1.89
The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS One (2008) 1.86
Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol (2002) 1.84
Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology (2009) 1.69
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol (2007) 1.69
Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. J Gen Virol (2007) 1.69
CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J Virol (2007) 1.61
Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol (2010) 1.59
Glycosylation of hepatitis C virus envelope proteins. Biochimie (2003) 1.56
Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J Virol (2005) 1.53
NS2 protein of hepatitis C virus interacts with structural and non-structural proteins towards virus assembly. PLoS Pathog (2011) 1.52
Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins. EMBO J (2002) 1.52
Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions. J Biol Chem (2004) 1.49
Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study. J Clin Microbiol (2005) 1.45
Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication. J Virol (2009) 1.43
Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol (2010) 1.41
CD81-dependent binding of hepatitis C virus E1E2 heterodimers. J Virol (2003) 1.38
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology (2012) 1.34
Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology (2002) 1.33
Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol (2007) 1.33
Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem (2006) 1.32
High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. J Gen Virol (2006) 1.31
Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment. J Biol Chem (2002) 1.28
Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology (2012) 1.26
Transmembrane domains of hepatitis C virus envelope glycoproteins: residues involved in E1E2 heterodimerization and involvement of these domains in virus entry. J Virol (2006) 1.25
Role of lipid metabolism in hepatitis C virus assembly and entry. Biol Cell (2009) 1.23
NMR structure and ion channel activity of the p7 protein from hepatitis C virus. J Biol Chem (2010) 1.21
Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry. J Virol (2005) 1.21
TaqMan amplification system with an internal positive control for HCV RNA quantitation. J Clin Virol (2004) 1.19
Functional hepatitis C virus envelope glycoproteins. Biol Cell (2004) 1.18
Identification of new functional regions in hepatitis C virus envelope glycoprotein E2. J Virol (2010) 1.15
Griffithsin has antiviral activity against hepatitis C virus. Antimicrob Agents Chemother (2011) 1.14
Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis. J Virol (2005) 1.11
Assembly of a functional HCV glycoprotein heterodimer. Curr Issues Mol Biol (2007) 1.10
Inhibition of hepatitis C virus infection in cell culture by small interfering RNAs. Mol Ther (2007) 1.09
The hepatitis C virus glycan shield and evasion of the humoral immune response. Viruses (2011) 1.07
Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry. Cell Microbiol (2007) 1.04
Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein. J Virol (2008) 1.03
Hepatitis C virus and natural compounds: a new antiviral approach? Viruses (2012) 1.03
Contribution of the charged residues of hepatitis C virus glycoprotein E2 transmembrane domain to the functions of the E1E2 heterodimer. J Gen Virol (2005) 1.01
Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles. J Gen Virol (2006) 1.01
BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma. Mol Cancer Res (2010) 1.00
Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study. J Clin Microbiol (2006) 0.98
Identification of basic amino acids at the N-terminal end of the core protein that are crucial for hepatitis C virus infectivity. J Virol (2010) 0.98
Role of the transmembrane domains of prM and E proteins in the formation of yellow fever virus envelope. J Virol (2003) 0.97
New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut (2012) 0.95
Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannosylphosphoryldolichol-deficient CHO mutant cell line. Glycobiology (2002) 0.95
Emergence of a genomic variant of the recombinant 2k/1b strain during a mixed Hepatitis C infection: a case report. J Clin Virol (2010) 0.94
Molecular typing and characterization of extended-spectrum TEM, SHV and CTX-M beta-lactamases in clinical isolates of Enterobacter cloacae. Res Microbiol (2008) 0.94
Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system. Hepatology (2006) 0.94